

Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Growth (Status and Outlook) 2026-2032

<https://marketpublishers.com/r/G1908D22F200EN.html>

Date: July 2026

Pages: 115

Price: US\$ 3,660.00 (Single User License)

ID: G1908D22F200EN

Abstracts

The global Peptide-Drug Conjugates(PDCs) CDMO Service market size is predicted to grow from US\$ 571 million in 2025 to US\$ 1854 million in 2032; it is expected to grow at a CAGR of 18.3% from 2026 to 2032.

Peptide-Drug Conjugates (PDCs) CDMO Service refers to contract development and manufacturing services for peptide-drug conjugates, typically covering peptide synthesis, linker and payload integration, conjugation process development, analytical method development and validation, quality studies, technology transfer, GMP manufacturing, scale-up, and commercial supply. The core of this service lies in achieving stable conjugation between peptide molecules, linkers, and small-molecule payloads while meeting the requirements for quality consistency, scalability, and regulatory compliance across drug development and commercialization stages. The upstream supply chain mainly includes protected amino acids, specialty amino acids, resin supports, linkers, cytotoxic payloads or other active small molecules, conjugation reagents, organic solvents, purification media, analytical consumables, and GMP packaging materials, while the main downstream customers are innovative pharmaceutical companies, biotechnology firms, and drug developers engaged in targeted delivery, peptide conjugates, and other novel conjugated modalities. The global gross margin of PDC CDMO services in 2025 is estimated at 30%-45%.

The PDC CDMO service market is currently moving from a stage focused on technical validation toward one centered on industrialization capability and integrated execution. As peptides gain broader value as targeting carriers and functional recognition elements, customer demand is no longer limited to peptide synthesis alone. Greater importance is now placed on linker design, payload integration, conjugation robustness, analytical characterization, and scalability in manufacturing. For clients, service

providers that can combine peptide synthesis, conjugation development, quality studies, and GMP manufacturing within one platform are becoming increasingly attractive, and competition is gradually shifting from isolated technical strengths to comprehensive delivery capability.

From a technology perspective, the market is expected to place greater emphasis on selective conjugation, advanced molecular characterization, impurity profile control, and consistency during scale-up. PDCs involve the integration of multiple components and present complex structural and quality attributes, which means development programs require strong capabilities in analytical methods, purification strategy, and process control. As more projects advance into later clinical stages, service providers will need to strengthen their expertise in peptide modification, linker chemistry, payload handling, and high-sensitivity analytical testing. At the same time, expectations for process robustness, batch consistency, and regulatory support will continue to increase.

The main drivers of market growth come from rising demand for novel targeted therapeutics, the gradual maturation of peptide conjugation technologies, and the growing willingness of innovative drug developers to outsource complex modalities. More pharmaceutical and biotechnology companies are relying on specialized external partners to reduce internal infrastructure costs, accelerate development timelines, and manage the complexity of integrating peptide, linker, and payload technologies. In addition, the expanding application potential of peptide-based conjugates in oncology, metabolic diseases, and other precision delivery fields continues to support demand for specialized CDMO services. As clinical programs accumulate and the supporting supply chain becomes more established, the market is likely to continue moving toward greater specialization and scale.

At the same time, the market faces several important constraints. PDC development depends on multiple critical steps, including peptide synthesis, linker selection, payload integration, and conjugation process control, and weakness in any one area can affect overall quality and development progress. The transition from laboratory development to GMP manufacturing also places much higher demands on production environments, analytical systems, documentation, and quality management, requiring sustained investment in equipment, talent, and compliance infrastructure. In addition, because the sector remains at a relatively early stage, project flow, commercialization maturity, and customer onboarding can still fluctuate, which means companies must carefully balance capacity expansion with actual order conversion. Over the longer term, the most competitive providers are likely to be those that can combine technical depth, development efficiency, quality systems, and industrial execution within an integrated

service platform.

LPI (LP Information)' newest research report, the "Peptide-Drug Conjugates(PDCs) CDMO Service Industry Forecast" looks at past sales and reviews total world Peptide-Drug Conjugates(PDCs) CDMO Service sales in 2025, providing a comprehensive analysis by region and market sector of projected Peptide-Drug Conjugates(PDCs) CDMO Service sales for 2026 through 2032. With Peptide-Drug Conjugates(PDCs) CDMO Service sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Peptide-Drug Conjugates(PDCs) CDMO Service industry.

This Insight Report provides a comprehensive analysis of the global Peptide-Drug Conjugates(PDCs) CDMO Service landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Peptide-Drug Conjugates(PDCs) CDMO Service portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Peptide-Drug Conjugates(PDCs) CDMO Service market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide-Drug Conjugates(PDCs) CDMO Service and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide-Drug Conjugates(PDCs) CDMO Service.

This report presents a comprehensive overview, market shares, and growth opportunities of Peptide-Drug Conjugates(PDCs) CDMO Service market by product type, application, key players and key regions and countries.

Segmentation by Type:

GMP Services

Non-GMP Services

Segmentation by Capacity Tier:

- Small-Scale Production
- Pilot-Scale Production
- Commercial-Scale Production

Segmentation by Therapeutic Area:

- Oncology
- Metabolic Diseases
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorder
- Other

Segmentation by Application:

- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutions
- Others

This report also splits the market by region:

- Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

WuXi TIDES

Porton

PeptiStar

Jiuzhou Pharmaceutical

CPC Scientific

Creative Peptides

Viva Biotech

KriSan Biotech

ChemExpress

CordenPharma

Almac Group

AmbioPharm

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size (2021-2032)
 - 2.1.2 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Region (2021 VS 2025 VS 2032)
 - 2.1.3 World Current & Future Analysis for Peptide-Drug Conjugates(PDCs) CDMO Service by Country/Region (2021, 2025 & 2032)
- 2.2 Peptide-Drug Conjugates(PDCs) CDMO Service Segment by Type
 - 2.2.1 GMP Services
 - 2.2.2 Non-GMP Services
 - 2.2.3 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type
 - 2.2.3.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Type (2021 VS 2025 VS 2032)
 - 2.2.3.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)
- 2.3 Peptide-Drug Conjugates(PDCs) CDMO Service Segment by Capacity Tier
 - 2.3.1 Small-Scale Production
 - 2.3.2 Pilot-Scale Production
 - 2.3.3 Commercial-Scale Production
 - 2.3.4 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier
 - 2.3.4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032)
 - 2.3.4.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier (2021-2026)
- 2.4 Peptide-Drug Conjugates(PDCs) CDMO Service Segment by Therapeutic Area

2.4.1 Oncology

2.4.2 Metabolic Diseases

2.4.3 Cardiovascular Diseases

2.4.4 Infectious Diseases

2.4.5 Neurological Disorder

2.4.6 Other

2.4.7 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area

2.4.7.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Therapeutic Area (2021 VS 2025 VS 2032)

2.4.7.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area (2021-2026)

2.5 Peptide-Drug Conjugates(PDCs) CDMO Service Segment by Application

2.5.1 Pharmaceutical Companies

2.5.2 Biotechnology Companies

2.5.3 Academic and Research Institutions

2.5.4 Others

2.5.5 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application

2.5.5.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Application (2021 VS 2025 VS 2032)

2.5.5.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

3 PEPTIDE-DRUG CONJUGATES(PDCS) CDMO SERVICE MARKET SIZE BY PLAYER

3.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Player

3.1.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2021-2026)

3.1.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Player (2021-2026)

3.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 PEPTIDE-DRUG CONJUGATES(PDCS) CDMO SERVICE BY REGION

- 4.1 Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2026)
- 4.2 Global Peptide-Drug Conjugates(PDCs) CDMO Service Annual Revenue by Country/Region (2021-2026)
- 4.3 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth (2021-2026)
- 4.4 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth (2021-2026)
- 4.5 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth (2021-2026)
- 4.6 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth (2021-2026)

5 AMERICAS

- 5.1 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country (2021-2026)
- 5.2 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026)
- 5.3 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2026)
- 6.2 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026)
- 6.3 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026)
- 6.4 China
- 6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

7 EUROPE

7.1 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country (2021-2026)

7.2 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026)

7.3 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service by Region (2021-2026)

8.2 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026)

8.3 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 GLOBAL PEPTIDE-DRUG CONJUGATES(PDCS) CDMO SERVICE MARKET FORECAST

10.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Region (2027-2032)

10.1.1 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Region (2027-2032)

10.1.2 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.1.3 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.1.4 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.1.5 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.2 Americas Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Country (2027-2032)

10.2.1 United States Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.2.2 Canada Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.2.3 Mexico Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.2.4 Brazil Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.3 APAC Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Region (2027-2032)

10.3.1 China Peptide-Drug Conjugates(PDCs) CDMO Service Market Forecast

10.3.2 Japan Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.3.3 Korea Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.3.4 Southeast Asia Market Peptide-Drug Conjugates(PDCs) CDMO Service

Forecast

10.3.5 India Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.3.6 Australia Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.4 Europe Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Country (2027-2032)

10.4.1 Germany Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.4.2 France Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.4.3 UK Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.4.4 Italy Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.4.5 Russia Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.5 Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Region (2027-2032)

10.5.1 Egypt Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.5.2 South Africa Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.5.3 Israel Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.5.4 Turkey Market Peptide-Drug Conjugates(PDCs) CDMO Service Forecast

10.6 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Type
(2027-2032)

10.7 Global Peptide-Drug Conjugates(PDCs) CDMO Service Forecast by Application
(2027-2032)

10.7.1 GCC Countries Market Peptide-Drug Conjugates(PDCs) CDMO Service
Forecast

11 KEY PLAYERS ANALYSIS

11.1 WuXi TIDES

11.1.1 WuXi TIDES Company Information

11.1.2 WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.1.3 WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross
Margin and Market Share (2021-2026)

11.1.4 WuXi TIDES Main Business Overview

11.1.5 WuXi TIDES Latest Developments

11.2 Porton

11.2.1 Porton Company Information

11.2.2 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.2.3 Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross
Margin and Market Share (2021-2026)

11.2.4 Porton Main Business Overview

11.2.5 Porton Latest Developments

11.3 PeptiStar

11.3.1 PeptiStar Company Information

11.3.2 PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.3.3 PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross
Margin and Market Share (2021-2026)

11.3.4 PeptiStar Main Business Overview

11.3.5 PeptiStar Latest Developments

11.4 Jiuzhou Pharmaceutical

11.4.1 Jiuzhou Pharmaceutical Company Information

11.4.2 Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service
Product Offered

11.4.3 Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service
Revenue, Gross Margin and Market Share (2021-2026)

11.4.4 Jiuzhou Pharmaceutical Main Business Overview

11.4.5 Jiuzhou Pharmaceutical Latest Developments

11.5 CPC Scientific

- 11.5.1 CPC Scientific Company Information
- 11.5.2 CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered
- 11.5.3 CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
- 11.5.4 CPC Scientific Main Business Overview
- 11.5.5 CPC Scientific Latest Developments
- 11.6 Creative Peptides
 - 11.6.1 Creative Peptides Company Information
 - 11.6.2 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered
 - 11.6.3 Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 11.6.4 Creative Peptides Main Business Overview
 - 11.6.5 Creative Peptides Latest Developments
- 11.7 Viva Biotech
 - 11.7.1 Viva Biotech Company Information
 - 11.7.2 Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered
 - 11.7.3 Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 11.7.4 Viva Biotech Main Business Overview
 - 11.7.5 Viva Biotech Latest Developments
- 11.8 KriSan Biotech
 - 11.8.1 KriSan Biotech Company Information
 - 11.8.2 KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered
 - 11.8.3 KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 11.8.4 KriSan Biotech Main Business Overview
 - 11.8.5 KriSan Biotech Latest Developments
- 11.9 ChemExpress
 - 11.9.1 ChemExpress Company Information
 - 11.9.2 ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered
 - 11.9.3 ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)
 - 11.9.4 ChemExpress Main Business Overview
 - 11.9.5 ChemExpress Latest Developments
- 11.10 CordenPharma
 - 11.10.1 CordenPharma Company Information

11.10.2 CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.10.3 CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

11.10.4 CordenPharma Main Business Overview

11.10.5 CordenPharma Latest Developments

11.11 Almac Group

11.11.1 Almac Group Company Information

11.11.2 Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.11.3 Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

11.11.4 Almac Group Main Business Overview

11.11.5 Almac Group Latest Developments

11.12 AmbioPharm

11.12.1 AmbioPharm Company Information

11.12.2 AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

11.12.3 AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Revenue, Gross Margin and Market Share (2021-2026)

11.12.4 AmbioPharm Main Business Overview

11.12.5 AmbioPharm Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Region (2021 VS 2025 VS 2032) & (\$ millions)

Table 2. Peptide-Drug Conjugates(PDCs) CDMO Service Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of GMP Services

Table 4. Major Players of Non-GMP Services

Table 5. Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Type (2021 VS 2025 VS 2032) & (\$ millions)

Table 6. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026) & (\$ millions)

Table 7. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)

Table 8. Major Players of Small-Scale Production

Table 9. Major Players of Pilot-Scale Production

Table 10. Major Players of Commercial-Scale Production

Table 11. Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Capacity Tier (2021 VS 2025 VS 2032) & (\$ millions)

Table 12. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Capacity Tier (2021-2026) & (\$ millions)

Table 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier (2021-2026)

Table 14. Major Players of Oncology

Table 15. Major Players of Metabolic Diseases

Table 16. Major Players of Cardiovascular Diseases

Table 17. Major Players of Infectious Diseases

Table 18. Major Players of Neurological Disorder

Table 19. Major Players of Other

Table 20. Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Therapeutic Area (2021 VS 2025 VS 2032) & (\$ millions)

Table 21. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Therapeutic Area (2021-2026) & (\$ millions)

Table 22. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area (2021-2026)

Table 23. Peptide-Drug Conjugates(PDCs) CDMO Service Market Size CAGR by Application (2021 VS 2025 VS 2032) & (\$ millions)

Table 24. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (\$ millions)

Table 25. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

Table 26. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Player (2021-2026) & (\$ millions)

Table 27. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Player (2021-2026)

Table 28. Peptide-Drug Conjugates(PDCs) CDMO Service Key Players Head office and Products Offered

Table 29. Peptide-Drug Conjugates(PDCs) CDMO Service Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 30. New Products and Potential Entrants

Table 31. Mergers & Acquisitions, Expansion

Table 32. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2026) & (\$ millions)

Table 33. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Region (2021-2026)

Table 34. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue by Country/Region (2021-2026) & (\$ millions)

Table 35. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Country/Region (2021-2026)

Table 36. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country (2021-2026) & (\$ millions)

Table 37. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Country (2021-2026)

Table 38. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026) & (\$ millions)

Table 39. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)

Table 40. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (\$ millions)

Table 41. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

Table 42. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2026) & (\$ millions)

Table 43. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Region (2021-2026)

Table 44. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type

(2021-2026) & (\$ millions)

Table 45. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (\$ millions)

Table 46. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Country (2021-2026) & (\$ millions)

Table 47. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Country (2021-2026)

Table 48. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026) & (\$ millions)

Table 49. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (\$ millions)

Table 50. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Region (2021-2026) & (\$ millions)

Table 51. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Type (2021-2026) & (\$ millions)

Table 52. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size by Application (2021-2026) & (\$ millions)

Table 53. Key Market Drivers & Growth Opportunities of Peptide-Drug Conjugates(PDCs) CDMO Service

Table 54. Key Market Challenges & Risks of Peptide-Drug Conjugates(PDCs) CDMO Service

Table 55. Key Industry Trends of Peptide-Drug Conjugates(PDCs) CDMO Service

Table 56. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Forecast by Region (2027-2032) & (\$ millions)

Table 57. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share Forecast by Region (2027-2032)

Table 58. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Forecast by Type (2027-2032) & (\$ millions)

Table 59. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Forecast by Application (2027-2032) & (\$ millions)

Table 60. WuXi TIDES Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 61. WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 62. WuXi TIDES Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 63. WuXi TIDES Main Business

Table 64. WuXi TIDES Latest Developments

Table 65. Porton Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO

Service Area Served and Its Competitors

Table 66. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 67. Porton Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 68. Porton Main Business

Table 69. Porton Latest Developments

Table 70. PeptiStar Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 71. PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 72. PeptiStar Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 73. PeptiStar Main Business

Table 74. PeptiStar Latest Developments

Table 75. Jiuzhou Pharmaceutical Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 76. Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 77. Jiuzhou Pharmaceutical Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 78. Jiuzhou Pharmaceutical Main Business

Table 79. Jiuzhou Pharmaceutical Latest Developments

Table 80. CPC Scientific Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 81. CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 82. CPC Scientific Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 83. CPC Scientific Main Business

Table 84. CPC Scientific Latest Developments

Table 85. Creative Peptides Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 86. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 87. Creative Peptides Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 88. Creative Peptides Main Business

Table 89. Creative Peptides Latest Developments

Table 90. Viva Biotech Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 91. Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 92. Viva Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 93. Viva Biotech Main Business

Table 94. Viva Biotech Latest Developments

Table 95. KriSan Biotech Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 96. KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 97. KriSan Biotech Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 98. KriSan Biotech Main Business

Table 99. KriSan Biotech Latest Developments

Table 100. ChemExpress Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 101. ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 102. ChemExpress Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 103. ChemExpress Main Business

Table 104. ChemExpress Latest Developments

Table 105. CordenPharma Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 106. CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 107. CordenPharma Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 108. CordenPharma Main Business

Table 109. CordenPharma Latest Developments

Table 110. Almac Group Details, Company Type, Peptide-Drug Conjugates(PDCs) CDMO Service Area Served and Its Competitors

Table 111. Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 112. Almac Group Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 113. Almac Group Main Business

Table 114. Almac Group Latest Developments

Table 115. AmbioPharm Details, Company Type, Peptide-Drug Conjugates(PDCs)

CDMO Service Area Served and Its Competitors

Table 116. AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Product Offered

Table 117. AmbioPharm Peptide-Drug Conjugates(PDCs) CDMO Service Revenue (\$ million), Gross Margin and Market Share (2021-2026)

Table 118. AmbioPharm Main Business

Table 119. AmbioPharm Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Peptide-Drug Conjugates(PDCs) CDMO Service Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth Rate (2021-2032) (\$ millions)

Figure 6. Peptide-Drug Conjugates(PDCs) CDMO Service Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Figure 7. Peptide-Drug Conjugates(PDCs) CDMO Service Sales Market Share by Country/Region (2025)

Figure 8. Peptide-Drug Conjugates(PDCs) CDMO Service Sales Market Share by Country/Region (2021, 2025 & 2032)

Figure 9. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type in 2025

Figure 10. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Capacity Tier in 2025

Figure 11. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Therapeutic Area in 2025

Figure 12. Peptide-Drug Conjugates(PDCs) CDMO Service in Pharmaceutical Companies

Figure 13. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market: Pharmaceutical Companies (2021-2026) & (\$ millions)

Figure 14. Peptide-Drug Conjugates(PDCs) CDMO Service in Biotechnology Companies

Figure 15. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market: Biotechnology Companies (2021-2026) & (\$ millions)

Figure 16. Peptide-Drug Conjugates(PDCs) CDMO Service in Academic and Research Institutions

Figure 17. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market: Academic and Research Institutions (2021-2026) & (\$ millions)

Figure 18. Peptide-Drug Conjugates(PDCs) CDMO Service in Others

Figure 19. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market: Others (2021-2026) & (\$ millions)

Figure 20. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application in 2025

Figure 21. Global Peptide-Drug Conjugates(PDCs) CDMO Service Revenue Market Share by Player in 2025

Figure 22. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Region (2021-2026)

Figure 23. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2021-2026 (\$ millions)

Figure 24. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2021-2026 (\$ millions)

Figure 25. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2021-2026 (\$ millions)

Figure 26. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2021-2026 (\$ millions)

Figure 27. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Value Market Share by Country in 2025

Figure 28. United States Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 29. Canada Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 30. Mexico Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 31. Brazil Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 32. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Region in 2025

Figure 33. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)

Figure 34. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

Figure 35. China Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 36. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 37. South Korea Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 38. Southeast Asia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 39. India Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 40. Australia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size

Growth 2021-2026 (\$ millions)

Figure 41. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Country in 2025

Figure 42. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)

Figure 43. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

Figure 44. Germany Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 45. France Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 46. UK Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 47. Italy Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 48. Russia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 49. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Region (2021-2026)

Figure 50. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Type (2021-2026)

Figure 51. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share by Application (2021-2026)

Figure 52. Egypt Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 53. South Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 54. Israel Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 55. Turkey Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 56. GCC Countries Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Growth 2021-2026 (\$ millions)

Figure 57. Americas Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 58. APAC Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 59. Europe Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 60. Middle East & Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 61. United States Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 62. Canada Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 63. Mexico Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 64. Brazil Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 65. China Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 66. Japan Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 67. Korea Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 68. Southeast Asia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 69. India Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 70. Australia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 71. Germany Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 72. France Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 73. UK Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 74. Italy Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 75. Russia Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 76. Egypt Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 77. South Africa Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 78. Israel Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

Figure 79. Turkey Peptide-Drug Conjugates(PDCs) CDMO Service Market Size

2027-2032 (\$ millions)

Figure 80. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share Forecast by Type (2027-2032)

Figure 81. Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Size Market Share Forecast by Application (2027-2032)

Figure 82. GCC Countries Peptide-Drug Conjugates(PDCs) CDMO Service Market Size 2027-2032 (\$ millions)

I would like to order

Product name: Global Peptide-Drug Conjugates(PDCs) CDMO Service Market Growth (Status and Outlook) 2026-2032

Product link: <https://marketpublishers.com/r/G1908D22F200EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1908D22F200EN.html>